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PTreatment of Obstructive Sleep
Apnea Is Associated With Decreased Cardiac
Death After Percutaneous Coronary Intervention
Andrew Cassar, MD, MRCP,* Timothy I. Morgenthaler, MD, FCCP,† Ryan J. Lennon, MS,‡
Charanjit S. Rihal, MD, FACC,§ Amir Lerman, MD, FACC§
Rochester, Minnesota
Objectives Our purpose was to compare outcomes of patients treated for obstructive sleep apnea (OSA) versus patients
with untreated OSA, all of whom had undergone percutaneous coronary intervention (PCI).
Background Obstructive sleep apnea has been associated with increases in fatal and nonfatal cardiovascular events. It is not
known whether treatment of OSA in patients who have had PCI results in a better outcome.
Methods In a retrospective cohort study, a group of patients with OSA diagnosed with polysomnography between 1992
and 2004 (apnea-hypopnea index 15) who subsequently underwent a PCI (n  371) were stratified according
to whether they were treated for OSA (n  175) or not (n  196). Main outcome measures were cardiac death,
general mortality, major adverse cardiac events (MACE) (severe angina, myocardial infarction, PCI, coronary ar-
tery bypass grafting, or death), and major adverse cardiac or cerebrovascular events (MACCE).
Results Patients treated for OSA had a statistically significant decreased number of cardiac deaths on follow-up when
compared with untreated OSA patients (3% [95% confidence interval (CI) 0% to 6%] vs. 10% [95% CI 5% to
14%] after 5 years, p  0.027), as well as a trend toward decreased all-cause mortality (p  0.058). There was
no difference in the number of MACE or MACCE between the 2 groups (p  0.91 and 0.96, respectively).
Conclusions Treatment of OSA is associated with a reduction in the number of cardiac deaths, but not in MACE or MACCE,
after PCI. Screening for and treating OSA in patients with coronary artery disease who may undergo PCI may
result in decreased cardiac death. (J Am Coll Cardiol 2007;50:1310–4) © 2007 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.028w
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coth sleep-disordered breathing and coronary artery disease
CAD) are common health problems. Sleep-disordered
reathing affects approximately 24% of men and 9% of
omen between the ages of 30 to 60 years (1). Coronary
rtery disease is a leading cause of death (2) in this and older
ge groups. Obstructive sleep apnea (OSA) has been asso-
iated with a 70% relative increased risk of cardiovascular
orbidity and mortality (3).
To clarify whether treatment of OSA is associated with a
etter prognosis in patients who have undergone percuta-
eous coronary intervention (PCI), we performed a retro-
pective analysis of the Mayo Sleep and PCI registries. The
urrent study was designed to test the hypotheses that in
atients who had undergone PCI, those treated for OSA
rom the *Department of Internal Medicine, †Division of Pulmonary and Critical
are, ‡Division of Biostatistics, and §Division of Cardiovascular Disease, Mayo
ollege of Medicine, Rochester, Minnesota.t
Manuscript received March 13, 2007; revised manuscript received May 29, 2007,
ccepted June 18, 2007.ould have improved outcomes compared with those not
reated for OSA.
ethods
tudy design, study population, and data collection. Af-
er approval by the Mayo Clinic Institutional Review Board,
ll patients who had undergone a polysomnogram at the
ayo Clinic, Rochester, Minnesota, from 1992 to 2004
ere identified (Fig. 1). This database of 23,602 patients
as crossed with the PCI database of the Mayo Clinic to
dentify those patients (n  519) who had a PCI up to the
nd of 2005. Only those patients with an apnea-hypopnea
ndex (AHI) of 15 were selected (n  376). Patients with
entral sleep apnea (n  5) were excluded. The patients
emaining (n  371) by definition had moderate (AHI 15
o 30) OSA (n 113) or severe (AHI30) OSA (n 258)
4). These patients’ medical records were reviewed for
ompliance to treatment for OSA, and the patients were
lassified as treated (n  175) or untreated (n  196). The
reated group was composed of 3 subgroups: 1) patients who
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October 2, 2007:1310–4 Treatment of OSA in Patients With PCIt follow-up visits showed compliance to treatment 3
onths after initiation of continuous positive airway pres-
ure (CPAP) (n  141); 2) patients who showed initial
ompliance to treatment to CPAP over the first 3 months
n  31) but further information about compliance beyond
months was not available; and 3) patients treated surgi-
ally with uvulopalatopharyngoplasty (n  3). Those pa-
ients who declined treatment, did not show compliance to
reatment, or in whom no information about treatment was
vailable were assigned to the untreated group (n  196).
ollow-up of patients was done with a telephone call or
uestionnaire by mail at 6 months, 1 year, and yearly
hereafter following their PCI procedure (5). The medical
ecords were reviewed by one investigator, and the patients’
haracteristics, risk factors, and procedural details were
xtracted. Six months of follow-up is available in 95% of the
atients and at least 12 months of follow-up in 89%. We
ompared the outcomes between untreated and treated
SA patients who underwent PCI.
utcome measures. The main outcome measures of inter-
st were cardiac death, general mortality, major adverse
ardiac events (MACE) (severe angina, myocardial infarc-
ion [MI], PCI, coronary artery bypass grafting [CABG], or
eath), and major adverse cardiac or cerebrovascular events
MACCE) (MACE or stroke).
tatistical analysis. Continuous variables are presented as
ean  standard deviation unless otherwise noted. Discrete
ariables are summarized as frequency (group percentage).
aplan-Meier estimates are used to summarize time-to-event
ariables, with day of PCI as the start date. Comparisons
Figure 1 Study Cohort Profile
AHI  apnea-hypoxia index; OSA  obstructive sleep apnea;
PCI  percutaneous coronary intervention; PSG  polysomnography.etween groups are made using 1-way analysis of variance,
v
oearson’s chi-square statistic, and
he log-rank test, respectively. All
ests are 2-tailed with a 0.05 sig-
ificance level. The overall type I
rror rate may be 0.05 due to
ultiple outcomes being tested.
nalyses were completed with
AS 9.1 software (SAS Institute,
ary, North Carolina).
esults
atient characteristics. The
aseline patient characteristics
or the treated and untreated
roups of patients with OSA are
hown in Table 1. The treated
roup had more severe OSA
han the untreated group at base-
ine as indicated by a higher av-
rage AHI (50 vs. 39, p 0.013)
nd the longer percentage time
ith an oxygen saturation below
0% (8.9% vs. 5.5%, p 0.06). Body mass index was higher
n the treated group (35.4  7.1 kg/m2 vs. 33.0  5.6
g/m2, p  0.001). Otherwise the 2 groups were similar for
ge, gender, family history of CAD, smoking, diabetes
ellitus, hypertension, hyperlipidemia, previous MI, PCI or
Abbreviations
and Acronyms
AHI  apnea-hypopnea
index
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
CI  confidence interval
CPAP  continuous
positive airway pressure
MACCE  major adverse
cardiac or cerebrovascular
events
MACE  major adverse
cardiac events
MI  myocardial infarct
OSA  obstructive sleep
apnea
PCI  percutaneous
coronary intervention
atient Characteristics
Table 1 Patient Characteristics
Variable
Treated OSA
(n  175)
Untreated OSA
(n  196)
Age, yrs 63.7 10.8 64.2 10.6
Male gender, n (%) 148 (85%) 177 (90%)
Body mass index, kg/m2 35.4 7.1 33.0 5.6*
Apnea-hypopnea index, median
(Q1, Q3)
50.0 (30.0, 71.0) 39.0 (24.5, 64.0)*
% time with O2 sat 90, median
(Q1, Q3)
8.9 (2.4, 31.8) 5.5 (1.7, 22.1)
Smoking status, n (%)
Never 54 (31%) 67 (35%)
Former 97 (56%) 102 (53%)
Current 22 (13%) 25 (13%)
Previous MI, n (%) 45 (26%) 63 (33%)
Prior PCI, n (%) 43 (25%) 65 (33%)
Prior CABG, n (%) 35 (20%) 46 (23%)
LVEF 40%, n (%) 104 (59%) 106 (54%)
Acute coronary syndrome, n (%) 123 (70%) 137 (70%)
Acute MI, n (%) 30 (17%) 36 (18%)
Aspirin on dismissal, n (%) 165 (94%) 185 (95%)
Beta-blocker on dismissal, n (%) 134 (77%) 139 (72%)
ACE inhibitor on dismissal, n (%) 94 (54%) 91 (47%)
Lipid-lowering drugs on dismissal,
n (%)
132 (75%) 148 (77%)
Clopidogrel on dismissal, n (%) 148 (85%) 152 (78%)
o significant differences between groups except where *p  0.05.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass grafting; LVEF  leftentricular ejection fraction; MImyocardial infarction; O
xygen saturation; PCI  percutaneous coronary interventSA obstructive sleep apnea; O2 sat
ion.
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Treatment of OSA in Patients With PCI October 2, 2007:1310–4ABG, peripheral arterial disease, cerebrovascular disease,
hronic obstructive pulmonary disease, and renal failure.
he percentage of patients presenting to PCI with acute
oronary syndrome or acute MI was similar in both groups.
here was no statistical difference in use of medications
etween the 2 groups.
ngiographic and procedural characteristics and outcome.
here were no differences between the 2 groups in the
ercentage of urgent/emergent PCI, number of vessels
iseased, total number of vessels treated, number of stents
nd type used, glycoprotein IIb/IIIa use, and Thrombolysis
n Myocardial Infarction score before and after PCI.
As regards complications during or just after PCI, the
reated sleep apnea group had less episodes of bradycardia
uring the PCI than the untreated sleep apnea group (1% vs.
%, p  0.007). All other arrhythmias, in-hospital death, and
n-hospital revascularization were similar for the 2 groups.
orbidity and mortality. Over a median follow-up of at
east 3 years, the treated OSA group had a statistically
ignificant reduced number of cardiac deaths when com-
ared with untreated OSA (3% [95% confidence interval
CI) 0% to 6%] vs. 10% [95% CI 5% to 14%] after 5 years,
 0.027) (Table 2, Figs. 2 and 3). Comparison of
ll-cause mortality between the treated and untreated sleep
pnea groups was just short of significance (p  0.058). At
years post-PCI, 3% in the treated OSA group suffered
ardiac death compared with 10% in the untreated group. A
imilar difference was observed for all-cause mortality with
1% and 17%, respectively. There was no difference in the
orbidity and Mortality
Table 2 Morbidity and Mortality
Main Outcome Measures
Untreated OSA
(n  196)
Treated OSA
(n  175) p Value
Follow-up cardiac death,
K-M (95% CI)
0.027
1 month 2% (0%–4%) 1% (0%–2%)
12 months 5% (2%–8%) 1% (0%–3%)
60 months 10% (5%–14%) 3% (0%–6%)
Follow-up mortality,
K-M (95% CI)
0.058
1 month 2% (0%–4%) 1% (0%–2%)
12 months 7% (3%–10%) 2% (0%–5%)
60 months 17% (11%–24%) 11% (4%–17%)
Follow-up MACE,
K-M (95% CI)
0.91
1 month 14% (9%–19%) 13% (8%–18%)
12 months 33% (26%–39%) 33% (25%–39%)
60 months 59% (50%–66%) 57% (47%–66%)
Follow-up MACCE,
K-M (95% CI)
0.96
1 month 14% (9%–19%) 13% (8%–18%)
12 months 33% (26%–39%) 33% (25%–39%)
60 months 61% (51%–68%) 57% (47%–66%)
I confidence interval; K-M Kaplan-Meier; MACCEmajor adverse cardiac or cerebrovascular
vents (major adverse coronary events or stroke); MACE major adverse coronary events (severe
ngina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting,
r death); OSA  obstructive sleep apnea.umber of MACE or MACCE between groups (p  0.91
nd 0.96, respectively).
After subgroup analysis, the severe (AHI 30) OSA
atients (131 treated vs. 127 untreated) also had a signifi-
ant decrease in cardiac death (3% [95% CI 0% to 6%] vs.
% [95% CI 3% to 14%] at 5 years, p  0.045) but not
ortality, MACE, or MACCE. There were no significant
ifferences between the moderate (AHI 15 to 30) OSA-
reated (n  44) and untreated (n  69) groups (for cardiac
eath 3% [95% CI 0% to 6%] vs. 11% [95% CI 1% to 20%]
t 5 years, p  0.24). This was likely due to the smaller
umber of moderate OSA patients under study.
Figure 2 Kaplan-Meier Estimates of Cardiac Death After PCI
Treatment of OSA was associated with a significantly lower incidence of
cardiac death after PCI (p  0.027 by log-rank test). Abbreviations as in Figure 1.
Figure 3 Kaplan-Meier Estimates
of All-Cause Mortality After PCI
A lower incidence of death after PCI in those treated for OSA was nearly
statistically significant (p  0.058 by log-rank test). Abbreviations as in Figure 1.
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October 2, 2007:1310–4 Treatment of OSA in Patients With PCIiscussion
ur study shows that patients with treated OSA undergo-
ng PCI have a significantly lower cardiac death rate than
atients with untreated OSA. The current study further
upports an important role for the diagnosis and treatment
f OSA in patients with CAD.
Obstructive sleep apnea is thought to be mechanistically
inked to atherosclerosis through the initiation of endothe-
ial injury by repetitive bursts of sympathetic activity, surges
f blood pressure, and oxidative stress brought on by apneas
nd episodic hypoxemia (6). The endothelial injury pro-
otes expression of adhesion molecules (7) with resultant
eukocyte accumulation and adhesion. Elevations of the
nflammatory mediators such as C-reactive protein (8),
levated plasma fibrinogen levels, exaggerated platelet activ-
ty, and reduced fibrinolytic capacity (9), increased plasma
iscosity (10), and endothelial dysfunction (11) are reported
n patients with OSA, even without CAD (12). Treatment
f OSA has been associated with reductions in circulating
nflammatory and thrombogenic factors (13) and improve-
ent in endothelial dysfunction (14), suggesting that treat-
ent of OSA should retard progression of atherosclerosis.
onsistent with this, some studies suggest that treatment of
SA reduces cardiovascular mortality and event rates (15).
ayashi et al. (16) determined that the oxygen desaturation
ndex over the night after PCI was the most significant
ndependent determinant of loss of lumen after 3 to 6
onths.
Our findings extend those of previous studies that dem-
nstrated an increased risk of both fatal and nonfatal
ardiovascular events in men with untreated severe sleep
pnea when compared with patients treated with CPAP
15). However, patients in the study by Marin et al. (15)
ere not selected on the basis of known CAD, whereas ours
ere limited to patients already showing advanced CAD.
ur study adds further information to the study of Milleron
t al. (17), which showed a significantly decreased incidence
f new cardiovascular events in patients with OSA and
AD with CPAP treatment, but our study includes more
atients. In this context, it is noteworthy that we did not
nd a significant overall difference in MACE or MACCE
etween treated and untreated patients. This may be sec-
ndary to the demographic differences between the studies.
n our study, all patients included had undergone PCI for
AD (70% for acute coronary syndrome) and our popula-
ion included 10% to 15% women. Our patients were put on
more aggressive medical plan with aspirin, clopidogrel,
tatins, and beta-blockers than those in the studies refer-
nced in the preceding text. This treatment, together with a
horter follow-up period (at least 3 years) compared with
ther studies, may have resulted in decreased MACE events
n our patients resulting in no significant difference in events
etween our treated and untreated OSA patients.
Apart from increased mortality from acute cardiovascularvents (3), patients with sleep apnea are also at increased iisk of sudden cardiac death due to arrhythmias. Gami et al.
18) described a 2.57 relative risk increase in cardiac death
etween midnight and 6 AM in patients with OSA. The
resumed mechanism (19) is that repetitive apnea-related
ypoxia and arousals stimulate the sympathetic nervous
ystem resulting in surges in blood pressure, increased
fterload, and myocardial oxygen demand. This may, in
urn, provoke myocardial ischemia and arrhythmias with
ncreased risk of sudden cardiac death. Studies have shown
hat CPAP treatment might abolish this trend (20). Ob-
tructive sleep apnea is also associated with an increased
revalence of atrial fibrillation (21), which is, in turn,
ssociated with an increased risk of death (22).
Studies have demonstrated a higher prevalence of OSA
nd nocturnal oxygen desaturation in patients with CAD
hen compared with control subjects (23,24). Mooe et al.
25) showed a statistically significant higher occurrence of
leep-disordered breathing in patients with CAD compared
ith control patients (37% vs. 20%). With over one-third of
atients with CAD having sleep-disordered breathing,
creening for and subsequently treating OSA in patients
ho may undergo PCI for CAD might be beneficial in
erms of decreasing mortality. A recent study by Wang et al.
26) recommends such screening and treatment of OSA in
atients with heart failure.
Limitations to our study include its retrospective
ature. Treatment was not randomly allocated. All pa-
ients were offered CPAP, but the patients who received
reatment were those who accepted and could tolerate
PAP. Patients were considered “treated” if they were
ompliant to treatment during the first 3 months after
tarting CPAP and “untreated” if they were not. It is
ossible that some patients may have been mistakenly
lassified as treated due to difficulty in assessing long-term
PAP compliance especially before the new CPAP ma-
hines with in-built compliance meters were introduced.
lso, patients who were classified as untreated may have
tarted CPAP treatment at a later date. Our retrospective
ethod could have compared patients who were more
ealth conscious and compliant with therapies in general
ith less adherent patients. Our study also does not dem-
nstrate that treatment for OSA after PCI may decrease
ortality, as OSA diagnosis and treatment occurred before
he PCI. A randomized prospective trial to test such a
ypothesis would be ideal but may not be possible, since
ithholding CPAP therapy from patients with OSA is not
ustifiable given the data available.
onclusions
reatment of OSA in patients who then undergo PCI
esulted in a statistically significant reduction in cardiac
eath but not in MACE or MACCE when compared
ith untreated OSA patients. Screening for, and treating,
SA in patients with CAD undergoing PCI may resultn decreased cardiac death and overall mortality.
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